There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on G1 Therapeutics Inc (GTHX) and MacroGenics (MGNX) with bullish sentiments.
G1 Therapeutics Inc (GTHX)
Cowen & Co. analyst Chris Shibutani maintained a Buy rating on G1 Therapeutics Inc on November 8. The company’s shares closed on Friday at $45.67.
According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 1.4% and a 36.7% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Lexicon Pharmaceuticals, and Pieris Pharmaceuticals.
Currently, the analyst consensus on G1 Therapeutics Inc is a Strong Buy with an average price target of $77, a 68.6% upside from current levels. In a report issued on November 8, H.C. Wainwright also maintained a Buy rating on the stock with a $75 price target.
.
See today’s analyst top recommended stocks >>
MacroGenics (MGNX)
In a report issued on November 8, Boris Peaker from Cowen & Co. maintained a Buy rating on MacroGenics. The company’s shares closed on Friday at $17.36, close to its 52-week low of $15.48.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 7.1% and a 42.6% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on MacroGenics is a Strong Buy with an average price target of $32, an 84.3% upside from current levels. In a report issued on October 30, H.C. Wainwright also maintained a Buy rating on the stock with a $34 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
